Single nucleotide polymorphism leads to daptomycin resistance causing amino acid substitution-T345I in MprF of clinically isolated MRSA strains.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
03
2020
accepted:
06
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Daptomycin (DAP) is one of the most potent antibiotics used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Due to an increase in its administration for combating MRSA infections, DAP non-susceptible (DAP-NS) MRSA strains have recently been reported in clinical settings. The presence of single nucleotide polymorphisms (SNPs) in the multiple peptide resistance factor (mprF) gene is the most frequently reported cause for the evolution of DAP-NS MRSA strains; however, there are some variations of SNPs that could lead to DAP-NS. In this study, we used two clinical MRSA strains, including DAP susceptible (DAP-S) and DAP-NS, isolated from the same patient at different time points. We introduced T345I SNP to mprF of the DAP-S MRSA strain using the gene exchange method with pIMAY vector. Further, we investigated the phenotype of the mutant strain, including drug susceptibility, cell surface positive charge, and growth speed. The mutant strain exhibited (i) resistance to DAP, (ii) up-regulation of positive surface charge, (iii) slower growth speed, and (iv) thickened cell walls. Hence, the SNP in mprF may have caused an up-regulation in MprF function, with a subsequent increase in positive surface charge. Cumulatively, these results demonstrated that the T345I amino acid substitution in mprF represents one of the primary causes of DAP-NS in MRSA strains.
Identifiants
pubmed: 33481910
doi: 10.1371/journal.pone.0245732
pii: PONE-D-20-09016
pmc: PMC7822245
doi:
Substances chimiques
Bacterial Proteins
0
Aminoacyltransferases
EC 2.3.2.-
mprF protein, Staphylococcus aureus
EC 2.3.2.-
Daptomycin
NWQ5N31VKK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245732Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Can J Infect Dis Med Microbiol. 2012 Summer;23(2):e48-50
pubmed: 23730321
Int J Infect Dis. 2002 Dec;6(4):302-8
pubmed: 12718825
Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8
pubmed: 17620372
Antimicrob Agents Chemother. 2014 Dec;58(12):7462-7
pubmed: 25288091
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30858203
J Clin Microbiol. 2008 Mar;46(3):1132-6
pubmed: 18199793
Antimicrob Agents Chemother. 1987 Jul;31(7):1014-6
pubmed: 2821883
PLoS One. 2012;7(1):e28316
pubmed: 22238576
Mol Microbiol. 2011 Apr;80(2):290-9
pubmed: 21306448
Front Microbiol. 2017 Nov 09;8:2199
pubmed: 29170657
Antimicrob Agents Chemother. 2009 Jun;53(6):2312-8
pubmed: 19332678
Antimicrob Agents Chemother. 2010 Dec;54(12):5222-33
pubmed: 20837752
PLoS One. 2018 Jun 7;13(6):e0198366
pubmed: 29879195
Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45
pubmed: 16723576
BMC Infect Dis. 2014 Aug 23;14:459
pubmed: 25149872
PLoS Pathog. 2011 Nov;7(11):e1002359
pubmed: 22102812
J Appl Microbiol. 2006 Oct;101(4):938-47
pubmed: 16968305
Antimicrob Agents Chemother. 2011 Aug;55(8):3922-8
pubmed: 21606222
PLoS Pathog. 2009 Nov;5(11):e1000660
pubmed: 19915718
Antimicrob Agents Chemother. 2000 Sep;44(9):2276-85
pubmed: 10952568
J Med Microbiol. 2008 Aug;57(Pt 8):1036-1038
pubmed: 18628509
Antimicrob Agents Chemother. 2011 Sep;55(9):4012-8
pubmed: 21709105
mBio. 2012 Mar 20;3(2):
pubmed: 22434850
Infect Dis (Lond). 2017 May;49(5):410-416
pubmed: 28116950
J Infect Chemother. 2014 Sep;20(9):527-34
pubmed: 25066429
Scand J Infect Dis. 2010 Dec;42(11-12):955-7
pubmed: 20942775
Front Microbiol. 2018 May 25;9:1086
pubmed: 29887848
Microbiology (Reading). 2011 Jun;157(Pt 6):1786-1797
pubmed: 21393369
J Antimicrob Chemother. 1998 Aug;42(2):199-209
pubmed: 9738837